drugset / Trial / NCT00174447

Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031

NCT00174447

Phase 3 Completed 43 enrolled Viatris Inc.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Open label extension study of Ziprasidone, evaluation of safety of long term use of ziprasidone

Timeline

Start
2001-10
Primary completion
2008-10
Completion
2008-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Ziprasidone Small molecule 40 mg Oral
Subject Ziprasidone Small molecule 60 mg Oral
Subject Ziprasidone Small molecule 80 mg Oral

Indications